The stock of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) increased by $0.02 on Monday to finish at $0.35, up 5.17 percent. The last five days have seen an average of 9,103,660 shares of common stock traded. 12 times new highs were reached in the current year, with a fall of -$0.6940. The average number of shares traded over the last 20 days was 3,904,295, while the average volume over the last 50 days totaled 4,376,114.
PIRS stock appreciated 58.93% since last month. On 08/02/23, the company’s shares reached a one-month low of $0.2050. The stock touched a high of $1.97 on 02/02/23, after rallying from a low of $0.16 in 52 weeks. The price of PIRS stock has declined by -66.73% or -$0.6940 this year, reaching a new high 12 times. Still, the stock price is down -82.44% from the 52-week high.
Insider Transactions
PIRS stock investors should be aware that Pieris Pharmaceuticals Inc. (PIRS) stock had its last reported insider trading activity 96 days ago on May 25. On May 25, Director KIRITSY CHRISTOPHER P acquired 10,000 shares at $0.85 each. This transaction resulted in the insider spending $8,500.
Valuation Metrics
Beta for the stock is 0.68. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1.35, the price-to-book (PB) ratio of 0.75.
Financial Health
For the three months ended June 29, Pieris Pharmaceuticals Inc.’s quick ratio was 1.90, while its current ratio was 1.90, indicating its ability to pay off its debt. Pieris Pharmaceuticals Inc.’s EBITDA margin for the year ended June 29 was -157.11%, whereas its operating margin stood at -86.30% for the same period. Based on annual data, it had gross profit of $69.38 million and revenue of $25.9 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. PIRS’s return on assets (ROA) during the last 12 months has been -29.70%. In the meantime, the return on equity (ROE) for the last 12 months was -90.40%.
Earnings Surprise
According to Pieris Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $20.06 million, while revenues rose by 81.56% to $1.94 million. It was predicted that Pieris Pharmaceuticals Inc.’s quarterly earnings would be $0.05, but it ended up being -$0.16, beating the consensus by 131.20%. EBITDA was $2.82 million for the quarter. At the end of Pieris Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 47.05 million, while its total debt was $12.83 million. Equity owned by shareholders amounts to $98.85 million.
Technical Picture
Here’s a quick look at Pieris Pharmaceuticals Inc.’s (PIRS) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 58.65%, suggesting the stock is Neutral, with a 195.15% historical volatility rate.
The stochastic %K and %D were 49.75% and 66.74% respectively, while the average true range (ATR) was 0.0669. Based on the 14-day stochastic reading of 42.44%, the RSI (14) reading is 57.53%. On the 9-day MACD Oscillator, the stock is at 0.0339, and the 14-day reading is at 0.0708.
Analyst Ratings
In its most recent analyst report, Robert W. Baird raised its rating on Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) to an Outperform. Prior to this, analysts firm rated the stock as a Neutral. Analysts have assigned Pieris Pharmaceuticals Inc. (PIRS) an Overweight rating. PIRS is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is PIRS’s price target for the next 12 months?
The current consensus forecast for the stock is between $7.00 and $7.00, with a median target price of $7.00. In analyzing these forecasts, the average price target given by analysts for Pieris Pharmaceuticals Inc. (PIRS) is $7.00.
